Search Results

There are 7267 results for: content related to: Use of Lipid-Lowering Agents in the Prevention of Cardiovascular Disease

  1. Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide

    The Journal of Clinical Pharmacology

    Volume 50, Issue 5, May 2010, Pages: 554–565, Dr Karen S. Brown, Ms Ingrid C. Armstrong, Dr Antonia Wang, Dr Joseph R. Walker, Dr Robert J. Noveck, Dr Dennis Swearingen, Dr Mark Allison, Dr James C. Kissling, Dr James Kisicki and Dr Daniel E. Salazar

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009349378

  2. You have full text access to this OnlineOpen article
    Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 5, May 2010, Pages: 384–392, Vivian A. Fonseca, Yehuda Handelsman and Bart Staels

    Version of Record online : 10 NOV 2009, DOI: 10.1111/j.1463-1326.2009.01181.x

  3. You have free access to this content
    Colesevelam: Potential Uses for the Newest Bile Resin

    Cardiovascular Drug Reviews

    Volume 23, Issue 1, March 2005, Pages: 15–30, Karen L. Steinmetz and Kristine S. Schonder

    Version of Record online : 7 JUN 2006, DOI: 10.1111/j.1527-3466.2005.tb00154.x

  4. Colesevelam for type 2 diabetes mellitus

    Intervention Review

    The Cochrane Library

    Cheow Peng Ooi and Seng Cheong Loke

    Published Online : 12 DEC 2012, DOI: 10.1002/14651858.CD009361.pub2

  5. You have full text access to this OnlineOpen article
    Lower Risk of Major Cardiovascular Events Associated with Adherence to Colesevelam HCI

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 33, Issue 10, October 2013, Pages: 1062–1070, Xin Ye, Chunlin Qian, Jiannong Liu and Wendy L. St. Peter

    Version of Record online : 24 JUN 2013, DOI: 10.1002/phar.1317

  6. Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation

    Diabetes, Obesity and Metabolism

    Volume 10, Issue 11, November 2008, Pages: 1004–1011, Eliot A. Brinton

    Version of Record online : 20 MAY 2008, DOI: 10.1111/j.1463-1326.2008.00903.x

  7. Quantitative Structure-Property Relationships Modeling to Predict In Vitro and In Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol)

    The Journal of Clinical Pharmacology

    Volume 49, Issue 10, October 2009, Pages: 1185–1195, Dr Joseph R. Walker, Dr Karen Brown, Dr Shashank Rohatagi, Dr Mohinder S. Bathala, Mr Chao Xu, Dr Prachi K. Wickremasingha, Dr Daniel E. Salazar and Dr Donald E. Mager

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009340783

  8. 2009 Annual Meeting October 18- October 21, 2009

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 29, Issue 10, October 2009, Pages: 181e–291e,

    Version of Record online : 14 MAR 2012, DOI: 10.1592/phco.29.10.181e

  9. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 1, January 2012, Pages: 40–46, R. R. Henry, V. R. Aroda, S. Mudaliar, W. T. Garvey, H. S. Chou and M. R. Jones

    Version of Record online : 21 NOV 2011, DOI: 10.1111/j.1463-1326.2011.01486.x

  10. What's New in Lipid Management?

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 23, Issue 9P2, September 2003, Pages: 34S–40S, Paul D. Thompson

    Version of Record online : 16 JAN 2012, DOI: 10.1592/phco.23.11.34S.32711

  11. You have free access to this content
    Colesevelam: new alternative or adjunctive treatment to statins

    Prescriber

    Volume 19, Issue 8, 19 April 2008, Pages: 27–31, Steve Chaplin and Paul Durrington

    Version of Record online : 12 MAY 2008, DOI: 10.1002/psb.228

  12. You have free access to this content
    Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia

    Clinical Cardiology

    Volume 24, Issue 6, June 2001, Pages: 467–474, Michael H. Davidson, Phillip Toth, Stuart Weiss, James Mckenney, Donald Hunninghake, Jonathan Isaacsohn, Joanne M. Donovan and Steven K. Burke

    Version of Record online : 3 FEB 2009, DOI: 10.1002/clc.4960240610

  13. Treatment of Dyslipidemia and Cardiovascular Outcomes: The Journey So Far—Is This the End for Statins?

    Clinical Pharmacology & Therapeutics

    Volume 96, Issue 2, August 2014, Pages: 192–205, S Zoungas, A J Curtis, J J McNeil and A M Tonkin

    Version of Record online : 11 APR 2014, DOI: 10.1038/clpt.2014.86

  14. Reducing Cardiovascular Risk and Managing Dyslipidemia in Women

    Nursing for Women's Health

    Volume 11, Issue 6, December 2007, Pages: 586–599, Susan J. Appel, Natalie A. Floyd and Emily J. Jones

    Version of Record online : 7 DEC 2007, DOI: 10.1111/j.1751-486X.2007.00245.x

  15. Ezetimibe: A Selective Cholesterol Absorption Inhibitor

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 23, Issue 11, November 2003, Pages: 1463–1474, Edith A. Nutescu and Nancy L. Shapiro

    Version of Record online : 16 JAN 2012, DOI: 10.1592/phco.23.14.1463.31942

  16. Pharmacologic Treatment of Type 2 Diabetic Dyslipidemia

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 24, Issue 12, December 2004, Pages: 1692–1713, Dr. Yong S. K. Moon and Dr. Moti L. Kashyap

    Version of Record online : 16 JAN 2012, DOI: 10.1592/phco.24.17.1692.52340

  17. Management of Elevated Low-Density Lipoprotein Cholesterol

    Practical Lipid Management: Concepts and Controversies

    Peter P. Toth, Kevin C. Maki, Pages: 63–104, 2008

    Published Online : 1 OCT 2008, DOI: 10.1002/9780470696873.ch5

  18. You have full text access to this OnlineOpen article
    Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial

    Hepatology

    Volume 56, Issue 3, September 2012, Pages: 922–932, Thuy-Anh Le, Joshua Chen, Christopher Changchien, Michael R. Peterson, Yuko Kono, Heather Patton, Benjamin L. Cohen, David Brenner, Claude Sirlin, Rohit Loomba and for the San Diego Integrated NAFLD Research Consortium (SINC)

    Version of Record online : 2 JUL 2012, DOI: 10.1002/hep.25731

  19. Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 2, February 2011, Pages: 137–143, S. K. Garg, P. J. Ritchie, E. G. Moser, J. K. Snell-Bergeon, B. J. Freson and R. M. Hazenfield

    Version of Record online : 27 DEC 2010, DOI: 10.1111/j.1463-1326.2010.01320.x

  20. Treating Dyslipidemic Patients with Lipid-Modifying and Combination Therapies

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 23, Issue 5, May 2003, Pages: 625–637, Chad R. Worz and Michael Bottorff

    Version of Record online : 16 JAN 2012, DOI: 10.1592/phco.23.5.625.32204